Research progression of interleukin 22 and inflammatory bowel disease
10.16571/j.cnki.1008-8199.2018.11.017
- VernacularTitle: 白细胞介素22与炎症性肠病的研究进展
- Author:
Chuang GAO
1
;
Xiao-bo DU
1
;
Dan-dan WANG
1
;
Bai-sui FENG
1
Author Information
1. Department of Gastroenterology, Second Affiliated Hospital of Zhengzhou University,Zhengzhou 450014,Henan,China
- Publication Type:Journal Article
- Keywords:
inflammatory bowel disease； innate lymphoid cells 3；aromatic hydrocarbon receptor；colitis associated cancer
- From:
Journal of Medical Postgraduates
2018;31(11):1196-1200
- CountryChina
- Language:Chinese
-
Abstract:
Inflammatory bowel disease (IBD) is a type of multi-etiology-induced, abnormal immune-mediated chronic recurrent inflammation of the intestine, which includes ulcerative colitis (UC) and Crohn's disease,(CD). IL-22 is a cytokine with unique biological properties. In the intestine, IL-22 has the ability to promote the expression of antimicrobial peptides and mucins that promote mucosal barrier integrity by activating the STAT3 pathway, and may promote intestinal epithelial cell regeneration and enhance intestinal epithelial cell barrier function. IL-22 is significantly increased in the intestinal mucosa of IBD patients. IL-22 can promote the repair of intestinal inflammatory damage, but with environmental changes, such as the level of expression of IL-23, T-bet, IL-22 binding protein, IL-22displayed dural characteristic, on the one hand, it can promote the repair of inflammatory injury, on the other hand it will increase the inflammatory injury response. This article mainly explains the origin of IL-22, its mode of action, and its application prospects in clinical treatment.
